Cargando…
A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor
BACKGROUND: The discovery of receptor activator of nuclear factor‐ĸB ligand (RANKL) as the final effector in the pathogenesis of osteoporosis has led to a better understanding of bone remodeling. When RANKL binds to its receptor (RANK), osteoclastic differentiation and activation are initiated. Here...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967917/ https://www.ncbi.nlm.nih.gov/pubmed/33784004 http://dx.doi.org/10.1002/ctm2.368 |